- Home
- XFOR vs GPRK Comparison
XFOR vs GPRK Comparison
Compare XFOR & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XFOR | GPRK |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.3M | 397.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XFOR | GPRK |
|---|---|---|
| Price | $3.15 | $8.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $34.67 | $8.50 |
| AVG Volume (30 Days) | 553.0K | ★ 807.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 1.44% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.65 |
| Revenue | $33,979,000.00 | ★ $525,938,000.00 |
| Revenue This Year | $1,307.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.49 |
| Revenue Growth | ★ 2925.74 | N/A |
| 52 Week Low | $1.35 | $5.66 |
| 52 Week High | $26.83 | $11.72 |
Technical Indicators
Market Signals| Indicator | XFOR | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 62.38 |
| Support Level | $3.49 | $7.53 |
| Resistance Level | $3.90 | $8.13 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 0.00 | 88.52 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.